Abound Wealth Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$160K Sell
630
-306
-33% -$71.3K 0.03% 116
2026
Q1
$229K Sell
936
-29
-3% -$6.75K 0.05% 83
2025
Q4
$200K Buy
965
+24
+3% +$4.75K 0.05% 89
2025
Q3
$175K Buy
941
+41
+5% +$7.02K 0.04% 89
2025
Q2
$138K Sell
900
-135
-13% -$20.8K 0.04% 102
2025
Q1
$172K Sell
1,035
-280
-21% -$43.8K 0.06% 77
2024
Q4
$190K Sell
1,315
-87
-6% -$13.5K 0.06% 71
2024
Q3
$227K Buy
1,402
+141
+11% +$22.5K 0.08% 59
2024
Q2
$184K Sell
1,261
-17
-1% -$2.53K 0.07% 61
2024
Q1
$202K Sell
1,278
-33
-3% -$5.25K 0.08% 61
2023
Q4
$205K Buy
1,311
+125
+11% +$19.2K 0.08% 59
2023
Q3
$185K Buy
1,186
+24
+2% +$3.96K 0.08% 56
2023
Q2
$192K Buy
1,162
+92
+9% +$14.8K 0.08% 54
2023
Q1
$166K Sell
1,070
-156
-13% -$25.2K 0.07% 56
2022
Q4
$217K Sell
1,226
-89
-7% -$15.4K 0.11% 46
2022
Q3
$215K Buy
+1,315
New +$223K 0.12% 41

Other funds holding JNJ

Abound Wealth Management's JNJ Position: Q2 2026 in Review

Abound Wealth Management reduced its Johnson & Johnson (JNJ) stake by 33% in Q2 2026, selling an estimated $71.3K and leaving 630 shares worth $160K. The position accounts for 0.03% of the portfolio, ranked #116.

Abound Wealth Management first reported a position in JNJ in Q3 2022 and has held it in 16 quarters since. The position peaked at $229K in Q1 2026. 4,655 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Abound Wealth Management held 630 shares of Johnson & Johnson worth $160K as of Q2 2026.
  • Abound Wealth Management sold 306 Johnson & Johnson shares in Q2 2026, an estimated $71.3K.
  • Johnson & Johnson made up 0.03% of Abound Wealth Management's portfolio in Q2 2026, its #116 holding.
  • Abound Wealth Management first reported a position in Johnson & Johnson in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Johnson & Johnson position peaked at $229K in Q1 2026.
  • 4,655 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.